Search Results - "Iyer, Kirti K"

Dendritic cell phenotype and function in a 3D co-culture model of patient-derived metastatic colorectal cancer organoids by Subtil, Beatriz, Iyer, Kirti K, Poel, Dennis, Bakkerus, Lotte, Gorris, Mark A J, Escalona, Jorge Cuenca, van den Dries, Koen, Cambi, Alessandra, Verheul, Henk M W, de Vries, I Jolanda M, Tauriello, Daniele V F

“…Colorectal cancer (CRC) remains one of the most aggressive and lethal cancers, with metastasis accounting for most deaths. As such, there is an unmet need for…”
Get full text

Lost in translation: Revisiting the use of tyrosine kinase inhibitors in colorectal cancer by Iyer, Kirti K., van Erp, Nielka P., Tauriello, Daniele V.F., Verheul, Henk M.W., Poel, Dennis

“…•Over 50 tyrosine kinase inhibitors (TKIs) have been approved by the FDA.•Around 42 TKIs have shown preclinical anticancer activity in colorectal cancer.•Only…”
Get full text

cDC2 plasticity and acquisition of a DC3‐like phenotype mediated by IL‐6 and PGE2 in a patient‐derived colorectal cancer organoids model by Subtil, Beatriz, Hoorn, Iris A. E., Cuenca‐Escalona, Jorge, Becker, Anouk M. D., Alvarez‐Begue, Mar, Iyer, Kirti K., Janssen, Jorien, Oorschot, Tom, Poel, Dennis, Gorris, Mark A. J., den Dries, Koen, Cambi, Alessandra, Tauriello, Daniele V. F., Vries, I. Jolanda M.

“…Metastatic colorectal cancer (CRC) is highly resistant to therapy and prone to recur. The tumor‐induced local and systemic immunosuppression allows cancer…”
Get full text

High-dose short-term osimertinib treatment is effective in patient-derived metastatic colorectal cancer organoids by Iyer, Kirti K., Poel, Dennis, Miggelenbrink, Anne, Kerkhof, Wouter, Janssen, Jorien, Bakkerus, Lotte, de Jong, Loek, van den Hombergh, Erik, Nagtegaal, Iris D., Tauriello, Daniele V. F., van Erp, Nielka P., Verheul, Henk M. W.

“…Most tyrosine kinase inhibitors (TKIs) have failed in clinical trials for metastatic colorectal cancer (mCRC). To leverage the additional lower-affinity…”
Get full text

Abstract 418: Elacridar potentiates sunitinib efficacy in colorectal cancer models by Poel, Dennis, Iyer, Kirti K., van Gasteren, Bob, Dagniaux, Beau, van den Hombergh, Erik, van Erp, Nielka P., Tauriello, Daniele V., Verheul, Henk M.

“…For unresectable metastatic colorectal cancer (mCRC), the main treatment strategy is combination chemotherapy, targeted therapy, or immunotherapy. Long-term…”
Get full text

Abstract 4028: High-dose short-exposure of osimertinib robustly inhibits growth of patient-derived metastatic colorectal cancer organoids by Iyer, Kirti K., Poel, Dennis, Miggelenbrink, Anne, Kerkhof, Wouter, van den Hombergh, Erik, de Jong, Loek A., van Erp, Nielka P., Tauriello, Daniele V., Verheul, Henk M.

“…Despite major interest in tyrosine kinase inhibitors (TKIs) as a treatment option for metastatic colorectal cancer (mCRC), almost all TKIs tested for mCRC fail…”
Get full text